AGP Executive Report
Last update: an hour agoAlzheimer’s Update: FDA cleared a once-weekly subcutaneous initiation option for Leqembi Iqlik (lecanemab-irmb), giving early patients an at-home autoinjector start and flexibility to switch between IV and SC dosing. Pipeline Momentum: Biogen’s diranersen (anti-tau ASO) Phase 2 CELIA data in early Alzheimer’s showed slowing on multiple endpoints, and the company is moving to confirmatory Phase 3. Neurology Beyond Pain: UCLA’s retrospective review suggests suzetrigine may help some people with refractory headache and facial pain disorders, including cases with limited options. Clinical Practice Shift: Dermatology experts are urging more deprescribing and medication reassessment to reduce polypharmacy harm as treatments linger on patient lists. Healthcare Operations & Safety: HHS pushed its HIPAA Security Rule overhaul to a long-term agenda, meaning organizations likely keep operating under current rules longer. Public Health Watch: A cyclospora outbreak is rising across multiple U.S. states, with Michigan reporting the highest numbers—food and water hygiene matter. Tech in Care: Taiwan’s smart-hospital push is driving interest in automated air-quality systems to reduce infection risk amid staffing shortages.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
![<![CDATA[Educating Patients About GLP-1s: Q&A with Kristen Hartzell, PharmD]]>](https://2c717466dc25cd7041c9-8eeda6a8ca964cf210ed223dbc947813.ssl.cf2.rackcdn.com/26669747-926667378-8e38c44403b4a8c12299980e24b687dfe25aec42-1920x1080-100x56.jpeg)
